A Phase 3 interventional study of rMenB+OMV NZ vaccine and Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 112 sites in 7 countries. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-05.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 7 in phase 3, and was the 19th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 10 Years to 25 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 9 · Phase 4 4
First in 2006; this study’s year is marked. 1 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,657 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 508 across the 21 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
71 studies in Meningococcal Infections by GlaxoSmithKline: none open now, 1 under way, none of them phase 3. Of 70 finished, 60 (86%) have results posted.
Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 3rd largest by enrollment of the 67 interventional ones that give a count, is one of 2 that started in 2020, is one of 34 in phase 3, and was the 67th registered.
GlaxoSmithKline’s Meningococcal Infections studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 71 in Meningococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the effectiveness of 2 doses or 3 doses of GSK's licenced meningococcal group B Bexsero (rMenB+OMV NZ) vaccine and of 2 doses of GSK's investigational combined meningococcal (MenABCWY) vaccine (GSK3536819A) in healthy adolescents and young adults. The immunogenicity and safety were evaluated in the study.
As per the feedback from the Center for Biologics Evaluation and Research (CBER), the scope of this post-marketing commitment study was extended to demonstrate the effectiveness, immunogenicity, and safety of GSK's investigational combined meningococcal ABCWY vaccine along with the rMenB+OMV NZ vaccine. Note that the rMenB+OMV and MenACWY vaccines provided to the MenB_0_2_6, MenB_0_6 group, and MenACWY group, respectively, at day 211 were only as part of the standard care of treatment and to maintain blinding. These vaccination schedules were not considered for any endpoint evaluations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female subjects of childbearing potential may be enrolled in the study, if the subject:
has agreed to continue adequate contraception until 30 days after completion of Visit 6.
Exclusion Criteria:
Medical conditions
History of any reaction or likely to be exacerbated by any component of the vaccine(s)/product(s).
Abnormal function or modification of the immune system resulting from:
Prior/Concomitant therapy
Prior/Concurrent clinical study experience
Other exclusions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 3 doses of rMenB+OMV NZ vaccine on Day 1, Day 61 and Day 181. Participants received 1 dose of MenACWY vaccine at Day 211 as a standard of care.
Combination Product: rMenB+OMV NZ vaccine · Biological: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY)
Participants received 2 doses of rMenB+OMV NZ vaccine on Day 1, and Day 181, 1 dose of MenACWY vaccine on Day 61. Participants received 1 dose of Placebo on Day 211 to maintain blinding.
Combination Product: rMenB+OMV NZ vaccine · Biological: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) · Combination Product: Placebo
Participants received 2 doses of MenABCWY lot 1 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
Combination Product: Placebo · Combination Product: MenABCWY-1
Participants received 2 doses of MenABCWY lot 2 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
Combination Product: Placebo · Combination Product: MenABCWY-2
Participants received 2 doses of MenABCWY lot 3 vaccine at Day 1 and Day 181 and 2 doses of placebo at Day 61 and Day 211.
Combination Product: Placebo · Combination Product: MenABCWY-3
Participants received 1 dose of MenACWY vaccine at Day 1,1 dose of placebo at Day 61 and 1 dose of rMenB+OMV NZ vaccine on Day 181. Participants received 1 dose of rMenB+OMV NZ vaccine on Day 211 as standard of care.
Combination Product: rMenB+OMV NZ vaccine · Biological: Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY) · Combination Product: Placebo
Participants received 2 doses of either MenABCWY Lot 1, Lot 2, or Lot 3 vaccine on Day 1 and Day 181 and 1 dose of placebo on Day 61. Participants received 1 dose of placebo on Day 211 to maintain blinding. To evaluate the effectiveness of 2 doses of the MenABCWY vaccines against rMenB+OMV and MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Combination Product: MenABCWY-1 · Combination Product: MenABCWY-2 · Combination Product: MenABCWY-3
Drug page: 4CMenB vaccine
rMenB+OMV NZ vaccine was administered intramuscularly.
Also known as: Bexsero
Drug page: MenACWY
MenACWY vaccine was administered intramuscularly.
Also known as: Menveo
Placebo was administered intramuscularly.
Also known as: NaCl, saline solution
Lot 1 of the MenABCWY vaccine was administered intramuscularly.
Lot 2 of the MenABCWY vaccine was administered intramuscularly.
Lot 3 of the MenABCWY vaccine was administered intramuscularly.
Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 3-dose (0,2,6-M), 2-dose(0,6-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY
The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 3 doses in MenB_0_2_6 group and 1 month after the 2 dose schedule in MenB_0_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains.
Time frame: At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group, and Day 31 for ACWY group)
Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose (0,2-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY
The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 2 doses in MenB_0_2_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains.
Time frame: At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule] and Day 31 for ACWY group)
Percentage of Participants Whose Sera Kill Greater Than or Equal to (>=) 70% of the Strains Tested Using Enc-hSBA at 1 Month After the 3-dose (0,2,6-M) Schedule of rMenB+OMV and 2-dose(0,6-M) Schedule of rMenB+OMV
The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains is above 65%.
Time frame: At 1 month after vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3-dose schedule] and MenB_0_6 group)
Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the 2-dose (0,2-M) Schedule of rMenB+OMV
The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains is above 65%.
Time frame: At 1 month after vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2-dose schedule])
Geometric Mean Titers (GMTs) Against Serogroups A, C, W and Y for Each Lot (ABCWY-1 Group, ABCWY-2 Group and ABCWY-3 Group) at 1 Month After the Last Vaccination of MenABCWY
Immune response was measured in terms of hSBA GMTs directed against serogroups A, C, W and Y. As pre-specified in the protocol, the data reported in this outcome measures data were presented for individual lots to demonstrate the consistency of the immune response of 3 lots (ABCWY- 1 Group, ABCWY-2 Group, and ABCWY-3 Group) of the ACWY component of the MenABCWY vaccine.
Time frame: At 1 month after the last vaccination of MenABCWY (Day 211)
Percentage of Participants With 4-fold Rise in hSBA Titers Against N. Meningitidis Serogroups A, C, W and Y at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group), Relative to Baseline
Four-fold rise is defined as: If the pre-vaccination hSBA titer is \< 4, then post-vaccination hSBA titer should be \>= 16 . If the pre-vaccination hSBA titer is \>= limit of detection (LOD) but \< LL of quantification (LLOQ), then post-vaccination hSBA titer should be \>= 4 times the LLOQ. If the pre-vaccination hSBA titer is \>= LLOQ, then post-vaccination hSBA titer should be \>= 4 times the pre-vaccination hSBA titer. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group, ABCWY pooled group to evaluate the immunological non-inferiority of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At 1 month after vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY Group) compared to Day 1 (baseline)
Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group)
The effectiveness (test-based) of 2 doses of MenABCWY vaccine when compared to 1 dose of MenACWY vaccine, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 31 for the ACWY group)
Percentage of Blood Samples With Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose (Pooled Lots) and 2-dose(0,2-M) Schedule of rMenB+OMV
The effectiveness was measured in terms of percentage of samples with bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule])
Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the Last Vaccination in the ABCWY Group (Pooled Lots)
The effectiveness (responder-based) of the MenABCWY vaccine is measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, being calculated based on Clopper Pearson method. Effectiveness is demonstrated Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains tested for MenABCWY is above 65%.
Time frame: At 1 month after the last vaccination of MenABCWY (Day 211)
Number of Participants With Any Solicited Local Adverse Events (AEs) After the First Study Intervention Administration
Assessed solicited local adverse events were injection or administration site = pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
Time frame: During 7 days after the first study intervention administration occurring at Day 1
Number of Participants With Any Solicited Local Adverse Events (AEs) After the Second Study Intervention Administration
Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
Time frame: During 7 days after the second study intervention administration occurring at Day 61
Number of Participants With Any Solicited Local Adverse Events (AEs) After the Third Study Intervention Administration
Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
Time frame: During 7 days after the third study intervention administration occurring at Day 181
Number of Participants With Any Solicited Systemic AEs After the First Study Intervention Administration
Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
Time frame: During 7 days after the first study intervention administration occurring at Day 1
Number of Participants With Any Solicited Systemic AEs After the Second Study Intervention Administration
Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
Time frame: During 7 days after the second study intervention administration occurring at Day 61
Number of Participants With Any Solicited Systemic AEs After the Third Study Intervention Administration
Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
Time frame: During 7 days after the third study intervention administration occurring at Day 181
Number of Participants With Any Unsolicited AEs After the First Study Intervention Administration
Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
Time frame: During the 30 days after the first study intervention administration occurring at Day 1
Number of Participants With Any Unsolicited AEs After the Second Study Intervention Administration
Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
Time frame: During the 30 days after the second study intervention administration occurring at Day 61
Number of Participants With Any Unsolicited AEs After the Third Study Intervention Administration
Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
Time frame: During the 30 days after the third study intervention administration occurring at Day 181
Number of Participants With SAEs, AEs Leading to Withdrawal, AESIs and Medically Attended AEs
A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it. Medically attended AEs are symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
Time frame: Throughout the study period (Day 1 to Day 361)
Percentage of Participants With 4-fold Rise in hSBA Titers Against N.Meningitidis Group B Strains at 1 Month After Last MenABCWY Dose(ABCWY Group-pooled Lots) and 1 Month After 2-dose(0,2-M) Schedule of rMenB+OMV NZ Relative to Baseline
The immunogenicity is measured as percentage of participants achieving a 4-fold rise in hSBA titers against N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). 4-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for participants with a pre-vaccination hSBA titre \<4; a post-vaccination hSBA titre ≥4 times the LLOQ for participants with a pre-vaccination hSBA titre ≥LOD and \<LLOQ; a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for the ABCWY_Pooled group and Day 91 for the MenB_0_2_6 Group [2-dose schedule]) compared to Day 1 (Baseline)
Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose and 3-dose (0,2,6-M), 2-dose(0,6-M) Schedule of rMenB+OMV and 1 Dose of MenACWY
The effectiveness of the 3 dose (0,2,6-M) and 2 dose (0,6-M ) schedule of rMenB+OMV NZ vaccine and 2 doses of MenABCWY vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group,ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for the MenB_0_2_6 group [3 dose schedule], MenB_0_6 group, ABCWY_Pooled group and Day 31 for the MenACWY group)
Percentage of Blood Samples Without Bactericidal Serum Activity Using Enc-hSBA Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose(0,6-M) Schedule of rMenB+OMV and 1 Dose of MenACWY
The effectiveness of the 2 dose (0,2-M) schedule of rMenB+OMV NZ vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4.
Time frame: At 1 month after the vaccination schedule (i.e., Day 91 for the MenB_0_2_6 group [2 dose schedule] and Day 31 for the MenACWY group)
Percentage of Participants Classified by Percentage of Serogroup B Invasive Disease Strains Killed Using Enc-hSBA in Each Subject at 1 Month After Vaccination Schedule for the MenB_0_2_6 Group [3 Dose], MenB_0_6 Group and Last MenABCWY Dose (Pooled Lots)
The percentage of participants classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At 1 month after the vaccination schedule (Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group)
Percentage of Participants Classified by Percentage of Serogroup B Invasive Disease Strains Killed Using Enc-hSBA in Each Subject at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)
The percentage of participants classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group.
Time frame: At 1 month after the vaccination schedule (Day 91 for MenB_0_2_6 group [2 dose schedule])
Percentage of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months and 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)
The immune response to rMenB+OMV NZ and MenABCWY vaccine is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains(M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At Day 1 (pre-vaccination) and1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3 dose schedule], MenB_0_6 group and ABCWY_Pooled group)
Percentage of Participants With hSBA Titers >= LLOQ for Each and All Serogroup B Indicator Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)
The immune response to rMenB+OMV NZ is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively).
Time frame: At Day 1 (pre-vaccination) and1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2 dose schedule])
Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months and 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)
The immune response to 3 dose (0,2,6-M), 2 dose (0,6-M) schedule of rMenB+OMV NZ and 2 doses of MenABCWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for subjects with a pre-vaccination hSBA titre \<4 a post-vaccination hSBA titer ≥4 times the LLOQ for subjects with a pre-vaccination hSBA titre ≥LOD and \<LLOQ a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group [3 dose schedule], MenB_0_6 group and ABCWY_Pooled group) compared to Day 1 (baseline)
Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2 Months)
The immune response to 2 dose (0,2-M) is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for participants with a pre-vaccination hSBA titre \<4 a post-vaccination hSBA titre ≥4 times the LLOQ for subjects with a pre-vaccination hSBA titre ≥LOD and \<LLOQ a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for subjects with a pre-vaccination hSBA titre ≥ LLOQ.
Time frame: At 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 [2-dose schedule]) compared to Day 1 (baseline)
hSBA Geometric Mean Titres (GMTs) Against Each of the N. Meningitidis Serogroup B Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months, 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)
The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At Day 1 (pre-vaccination) and at 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group)
hSBA GMTs Against Each of the N. Meningitidis Serogroup B Strains at Day 1 and at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)
The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) were calculated, with their associated 2-sided 95% CIs.
Time frame: At Day 1 (pre-vaccination) and at 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group[2-dose schedule])
hSBA Geometric Mean Ratios (GMRs) for Each of the N. Meningitidis Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2,6-months, 0,6-months) and Last Dose of MenABCWY (ABCWY Group-pooled Lots)
The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At 1 month after the vaccination schedule (i.e., Day 211 for MenB_0_2_6 group (3 dose schedule), MenB_0_6 group and ABCWY_Pooled group) compared to Day 1 (baseline)
hSBA GMRs for Each of the N. Meningitidis Serogroup B Strains at 1 Month After Vaccination With rMenB+OMV NZ (0,2-months)
The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs.
Time frame: At 1 month after the vaccination schedule (i.e., Day 91 for MenB_0_2_6 group [2-dose schedule]) compared to Day 1 (baseline)
Percentage of Participants With hSBA Titers >= LLOQ for Each of the N. Meningitidis Serogroups A,C,W,Y at Day 1 and at 1 Month After the First and the Last MenABCWY Vaccination for ABCWY_Pooled Group and 1 Month After the MenACWY Vaccine for ACWY Group
The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y after vaccination compared to baseline (Day 1) and expressed as the percentage of participants with hSBA titers \>= LLOQ for serogroups A, C, W and Y at baseline and 1 month after vaccination schedule of MenABCWY and MenACWY vaccines. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose])
Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the N. Meningitidis Serogroups A, C, W and Y at 1 Month After the First MenABCWY Dose for ABCWY_Pooled Group Compared to the MenACWY Vaccine for ACWY Group Relative to Baseline (Day 1)
The immune response to MenABCWY vaccine compared to MenACWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroups A, C, W and Y at Day 31 compared to baseline (Day 1). Four-fold rise is defined as: - If the pre-vaccination hSBA titer is \< 4, then post-vaccination hSBA titer should be ≥ 16. - If the pre-vaccination hSBA titer is ≥ LOD but \< LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the LLOQ. - If the pre-vaccination hSBA titer is ≥ LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the pre-vaccination hSBA titer. The corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled group] and for ACWY Group) relative to baseline (Day 1)
hSBA GMTs Against Each of the N. Meningitidis Serogroups A, C, W and Y at Day 1 and 1 Month After the First and the Last MenABCWY Vaccination for the ABCWY_Pooled Group and at 1 Month After the MenACWY Vaccination for ACWY Group
The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroups A, C, W and Y, the GMTs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose])
GMRs for Each of the N. Meningitidis Serogroups A, C, W and Y at 1 Month After the First and the Last MenABCWY Vaccination for the ABCWY _Pooled Group and at 1 Month After the MenACWY Vaccination for ACWY Group
The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y. For each N. meningitidis serogroups A, C, W and Y, the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose]) compared to baseline (Day 1)
Total Immunoglobulin G (IgG) Antibodies Concentrations Against N. Meningitidis Serogroups A, C, W and Y at Day 1 and 1 Month After the First and the Last MenABCWY Vaccination for ABCWY _Pooled Group and 1 Month After the MenACWY Vaccination for ACWY Group
The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring the total IgG in terms of electrochemiluminescence-based multiplex (ECL) geometric mean concentrations (GMCs) which was an alternative assay to Enzyme-Linked Immunosorbent Assay (ELISA). ECL (validated assay) was used because ELISA is not validated. As pre- specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
Time frame: At Day 1, and 1 month after vaccination schedule (i.e, at Day 31 for ABCWY group [pooled lots -first dose] and for ACWY Group, and at Day 211 for ABCWY group [pooled lots - second dose])
As pre-specified in protocol: * Participant flow, Baseline characteristics, Effectiveness and immunogenicity data are presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group. * Lot-to-lot consistency analysis data are presented for individual ABCWY lot groups (ABCWY-1, ABCWY-2 and ABCWY-3) as Lot-to-Lot assessment was limited to the objective on lot-to-lot consistency only.
| Milestone | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| Started | 897 | 906 | 1657 | 178 |
| Abcwy-1 group | 0 | 0 | 549 | 0 |
| Abcwy-2 group | 0 | 0 | 554 | 0 |
| Abcwy-3 group | 0 | 0 | 554 | 0 |
| Completed | 797 | 811 | 1497 | 163 |
| Not completed | 100 | 95 | 160 | 15 |
| Withdrew: Adverse event | 7 | 6 | 11 | 1 |
| Withdrew: Lost to follow-up | 32 | 36 | 69 | 4 |
| Withdrew: Protocol violation | 8 | 8 | 16 | 1 |
| Withdrew: Withdrawal by subject | 46 | 38 | 54 | 7 |
| Withdrew: Migrated / moved from the study area | 6 | 7 | 9 | 1 |
| Withdrew: Other | 1 | 0 | 1 | 1 |
The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 3 doses in MenB_0_2_6 group and 1 month after the 2 dose schedule in MenB_0_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains.
| Percentage of blood samples | MenB_0_2_6 Group | MenB_0_6 Group | ACWY Group |
|---|---|---|---|
| Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 3-dose (0,2,6-M), 2-dose(0,6-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY | 13.3 | 14.4 | 79 |
The effectiveness (test-based) of rMenB+OMV vaccine at 1 month after the 2 doses in MenB_0_2_6 group when compared to one dose of MenACWY vaccination in ACWY group, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using endogenous complement human Serum Bactericidal Assay (enc-hSBA), which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. Participants were randomly selected for testing against each strain therefore only a subset of participants were tested for each of the strains.
| Percentage of blood samples | MenB_0_2_6 Group | ACWY Group |
|---|---|---|
| Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic US N. Meningitidis Serogroup B Strains at 1 Month After the 2-dose (0,2-M) Vaccination Schedule of rMenB+OMV and 1 Dose of MenACWY | 16.8 | 79 |
The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains is above 65%.
| Percentage of participants | MenB_0_2_6 Group | MenB_0_6 Group |
|---|---|---|
| Percentage of Participants Whose Sera Kill Greater Than or Equal to (>=) 70% of the Strains Tested Using Enc-hSBA at 1 Month After the 3-dose (0,2,6-M) Schedule of rMenB+OMV and 2-dose(0,6-M) Schedule of rMenB+OMV | 93.4 ± 91.2 | 89.8 ± 87.2 |
The effectiveness (responder-based) of the rMenB+OMV NZ vaccine was measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, calculated based on Clopper Pearson method. Effectiveness is demonstrated if Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains is above 65%.
| Percentage of participants | MenB_0_2_6 Group |
|---|---|
| Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the 2-dose (0,2-M) Schedule of rMenB+OMV | 84.8 ± 81.8 |
Immune response was measured in terms of hSBA GMTs directed against serogroups A, C, W and Y. As pre-specified in the protocol, the data reported in this outcome measures data were presented for individual lots to demonstrate the consistency of the immune response of 3 lots (ABCWY- 1 Group, ABCWY-2 Group, and ABCWY-3 Group) of the ACWY component of the MenABCWY vaccine.
| Titers | ABCWY-1 Group | ABCWY-2 Group | ABCWY-3 Group |
|---|---|---|---|
| Men A | 336.4 (299.3 to 378.0) | 349.9 (311.5 to 393.0) | 390.4 (347.4 to 438.8) |
| Men C | 1036.7 (877.6 to 1224.5) | 1130.2 (958.1 to 1333.4) | 888.4 (752.1 to 1049.2) |
| Men W | 564.5 (497.9 to 639.9) | 635.5 (561.0 to 719.9) | 640.1 (564.6 to 725.6) |
| Men Y | 536.7 (464.5 to 620.2) | 623.9 (540.4 to 720.2) | 644.3 (557.6 to 744.6) |
Four-fold rise is defined as: If the pre-vaccination hSBA titer is \< 4, then post-vaccination hSBA titer should be \>= 16 . If the pre-vaccination hSBA titer is \>= limit of detection (LOD) but \< LL of quantification (LLOQ), then post-vaccination hSBA titer should be \>= 4 times the LLOQ. If the pre-vaccination hSBA titer is \>= LLOQ, then post-vaccination hSBA titer should be \>= 4 times the pre-vaccination hSBA titer. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group, ABCWY pooled group to evaluate the immunological non-inferiority of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Percentage of participants | ABCWY_Pooled | ACWY Group |
|---|---|---|
| Men A | 97.0 (95.9 to 97.9) | 85.7 (77.8 to 91.6) |
| Men C | 97.2 (96.1 to 98.1) | 50.0 (40.5 to 59.5) |
| Men W | 97.0 (95.9 to 97.9) | 61.7 (52.2 to 70.6) |
| Men Y | 96.7 (95.6 to 97.7) | 69.7 (60.7 to 77.8) |
The effectiveness (test-based) of 2 doses of MenABCWY vaccine when compared to 1 dose of MenACWY vaccine, against a panel of N. meningitidis serogroup B strains was measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for ACWY group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Percentage of blood samples | ABCWY_Pooled | ACWY Group |
|---|---|---|
| Percentage of Blood Samples Without Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After Last MenABCWY Vaccination (Pooled Lots) and MenACWY Vaccination (for the ACWY Group) | 17.4 | 79 |
The effectiveness was measured in terms of percentage of samples with bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Percentage of blood samples | MenB_0_2_6 Group | ABCWY_Pooled |
|---|---|---|
| Percentage of Blood Samples With Bactericidal Serum Activity Against Each of the Endemic U.S N. Meningitidis Serogroup B Strains at 1 Month After the Last MenABCWY Dose (Pooled Lots) and 2-dose(0,2-M) Schedule of rMenB+OMV | 83.1 | 82.5 |
The effectiveness (responder-based) of the MenABCWY vaccine is measured in terms of percentage of participants whose sera kill \>=70% of the strains tested using enc-hSBA, being calculated based on Clopper Pearson method. Effectiveness is demonstrated Lower Limit (LL) of the two-sided 97.5% CI for the percentages of participants whose sera kill ≥70% of strains tested for MenABCWY is above 65%.
| Percentage of participants | ABCWY_Pooled |
|---|---|
| Percentage of Participants Whose Sera Kill >=70% of the Strains Tested Using Enc-hSBA at 1 Month After the Last Vaccination in the ABCWY Group (Pooled Lots) | 84.1 ± 81.4 |
Assessed solicited local adverse events were injection or administration site = pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
| Participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| Pain | 807 | 819 | 1503 | 67 |
| Erythema | 90 | 86 | 216 | 11 |
| Swelling | 87 | 89 | 217 | 11 |
| Induration | 60 | 64 | 150 | 7 |
Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
| Participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| Pain | 714 | 224 | 205 | 30 |
| Erythema | 89 | 26 | 5 | 1 |
| Swelling | 99 | 22 | 5 | 1 |
| Induration | 67 | 19 | 6 | 0 |
Assessed solicited local adverse events were injection or administration site pain, erythema, swelling, induration. Any = occurrence of the adverse event regardless of intensity grade. Any erythema and swelling = adverse event reported with a surface diameter greater than 0 millimeters. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
| Participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| Pain | 677 | 676 | 1258 | 126 |
| Erythema | 118 | 87 | 168 | 11 |
| Swelling | 107 | 85 | 176 | 13 |
| Induration | 52 | 57 | 114 | 12 |
Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
| Participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| Fatigue | 423 | 414 | 828 | 78 |
| Nausea | 112 | 111 | 242 | 27 |
| Myalgia | 92 | 106 | 242 | 13 |
| Arthralgia | 56 | 70 | 133 | 17 |
| Headache | 358 | 330 | 681 | 69 |
| Fever (C) | 19 | 17 | 55 | 3 |
Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
| Participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| Fatigue | 372 | 228 | 345 | 36 |
| Nausea | 104 | 56 | 85 | 18 |
| Myalgia | 110 | 46 | 55 | 3 |
| Arthralgia | 72 | 332.0 | 35 | 6 |
| Headache | 301 | 223 | 332 | 31 |
| Fever (C) | 22 | 12 | 18 | 1 |
Assessed solicited systemic AEs were fatigue, nausea, myalgia, arthralgia, headache and fever \[temperature \>= 38.0°C\]. Any = occurrence of the adverse event regardless of intensity grade or relation to study vaccination. No solicited AEs were collected after vaccination on Day 211 because these vaccines were administered as part of standard of care and to maintain blinding. As pre- specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
| Participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| Fatigue | 374 | 341 | 602 | 56 |
| Nausea | 94 | 84 | 147 | 14 |
| Myalgia | 106 | 109 | 168 | 17 |
| Arthralgia | 71 | 53 | 104 | 7 |
| Headache | 302 | 284 | 509 | 39 |
| Fever (C) | 21 | 23 | 27 | 2 |
Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
| Participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| Number of Participants With Any Unsolicited AEs After the First Study Intervention Administration | 90 | 124 | 217 | 29 |
Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
| Participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| Number of Participants With Any Unsolicited AEs After the Second Study Intervention Administration | 106 | 88 | 160 | 15 |
Unsolicited AEs are defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside the specified period of follow-up for solicited symptoms were reported as an unsolicited AE. Any Unsolicited AEs (including Serious adverse events (SAEs), AEs leading to withdrawal, Adverse event of special interest (AESIs) and medically attended AEs were collected during 30 days after vaccination 1-3. For vaccination on Day 211 (Vaccination 4), conducted as part of standard of care and to maintain blinding, no eDiary data or all unsolicited AEs were collected for the 30 days following vaccination. However, SAEs, AEs leading to withdrawal, AESIs and medically attended AEs were collected throughout study duration. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
| Participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| Number of Participants With Any Unsolicited AEs After the Third Study Intervention Administration | 96 | 94 | 183 | 19 |
A SAEs is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity and is a congenital anomaly/birth defect in the offspring of a study subject. AESIs are predefined (serious or non-serious) AEs of scientific and medical concern specific to the product or program, for which ongoing monitoring and rapid communication by the investigator to the sponsor can be appropriate, because such an event might warrant further investigation to characterize and understand it. Medically attended AEs are symptoms or illnesses requiring hospitalization, or emergency room visit, or visit to/by a health care provider. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
| Participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| SAEs | 20 | 22 | 25 | 5 |
| AEs leading to withdrawal | 6 | 4 | 4 | 1 |
| AESIs | 1 | 1 | 6 | 0 |
| medically attended AEs | 238 | 288 | 479 | 44 |
The immunogenicity is measured as percentage of participants achieving a 4-fold rise in hSBA titers against N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). 4-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for participants with a pre-vaccination hSBA titre \<4; a post-vaccination hSBA titre ≥4 times the LLOQ for participants with a pre-vaccination hSBA titre ≥LOD and \<LLOQ; a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ. As pre-specified in the protocol, data reported in this outcome measure were presented for MenB_0_2_6 Group and ABCWY pooled group to evaluate the effectiveness of 2 doses of the MenABCWY vaccines against MenACWY vaccines, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Percentage of participants | MenB_0_2_6 Group | ABCWY_Pooled |
|---|---|---|
| fHbp (M14459) Ab | 74.7 (71.3 to 77.8) | 79.7 (76.5 to 82.7) |
| NadA (96217) Ab | 96.4 (94.7 to 97.6) | 92.7 (90.5 to 94.5) |
| NHBA (M13520) Ab | 58.6 (54.9 to 62.3) | 61.9 (58.2 to 65.6) |
| PorA (NZ98/254) Ab | 53.3 (49.5 to 57.0) | 42.2 (38.4 to 46.1) |
The effectiveness of the 3 dose (0,2,6-M) and 2 dose (0,6-M ) schedule of rMenB+OMV NZ vaccine and 2 doses of MenABCWY vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group,ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Percentage of blood samples | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group |
|---|---|---|---|---|
| Meningitis B M10713 Ab | 0.4 | 0.4 | 1.2 | 15.6 |
| Meningitis B M08641 Ab | 6.6 | 6.2 | 8.0 | 96.6 |
| Meningitis B M12898 Ab | 8.4 | 11.4 | 12.1 | 68.1 |
| Meningitis B M09150 Ab | 5.2 | 8.5 | 12.6 | 73.0 |
| Meningitis B M09401 Ab | 50.2 | 46.5 | 57 | 98.0 |
| Meningitis B M07463 Ab | 1.5 | 1.8 | 3.5 | 49 |
| Meningitis B M10496 Ab | 54.4 | 47.9 | 68.9 | 100.0 |
| Meningitis B M14530 Ab | 2.1 | 1.6 | 3.2 | 100.0 |
| Meningitis B M15668 Ab | 0.8 | 2.2 | 0.8 | 87.8 |
| Meningitis B M14028 Ab | 2.8 | 5.7 | 4.9 | 100 |
| Meningitis B M09909 Ab | 79.1 | 83.4 | 86.2 | 100.0 |
| Meningitis B M14385 Ab | 0.9 | 0.8 | 0.0 | 16.3 |
| Meningitis B M07992 Ab | 0.4 | 0.0 | 0.4 | 0.0 |
| Meningitis B M09155 Ab | 1.7 | 2.0 | 1.3 | 97.8 |
| Meningitis B M13085 Ab | 13.5 | 27.5 | 26.6 | 69.3 |
| Meningitis B M18303 Ab | 2.9 | 4.0 | 9.5 | 100.0 |
| Meningitis B M18711 Ab | 5.2 | 4.2 | 9.5 | 75.8 |
| Meningitis B M15009 Ab | 11.8 | 20.5 | 31.8 | 86.5 |
| Meningitis B M07773 Ab | 0.7 | 0.4 | 0.4 | 74.3 |
| Meningitis B M09662 Ab | 61.4 | 50.8 | 66.3 | 95.8 |
| Meningitis B M18483 Ab | 3.0 | 5.1 | 3.7 | 72.2 |
| Meningitis B M11906 Ab | 23.7 | 30.3 | 39.9 | 84.7 |
| Meningitis B M14987 Ab | 1.2 | 8.8 | 12.7 | 68.6 |
| Meningitis B M12014 Ab | 0.4 | 0.7 | 1.2 | 67.4 |
| Meningitis B M18200 Ab | 6.3 | 14.8 | 14.9 | 33.7 |
| Meningitis B M08912 Ab | 0.4 | 0.0 | 0.0 | 0.0 |
| Meningitis B M16748 Ab | 0.8 | 0.0 | 0 | 0.0 |
| Meningitis B M08152 Ab | 22.4 | 25.3 | 32.8 | 66.8 |
| Meningitis B M09973 Ab | 0.8 | 1.1 | 3.0 | 83.3 |
| Meningitis B M15352 Ab | 8.9 | 8.4 | 17.8 | 97.0 |
| Meningitis B M15165 Ab | 0.0 | 1.2 | 2.1 | 92.9 |
| Meningitis B M08127 Ab | 0.7 | 0.4 | 0.7 | 84.3 |
| Meningitis B M18347 Ab | 45.4 | 50.9 | 51.8 | 82.1 |
| Meningitis B M12500 Ab | 0.9 | 2.4 | 2.5 | 95.3 |
| Meningitis B M07499 Ab | 70.7 | 75.7 | 80.1 | 100.0 |
| Meningitis B M09960 Ab | 1.2 | 0 | 0 | 3.0 |
| Meningitis B M18045 Ab | 0 | 0.4 | 0 | 92.7 |
| Meningitis B M10548 Ab | 8.1 | 11.9 | 12.5 | 74.1 |
| Meningitis B M09354 Ab | 1.2 | 1.3 | 0 | 80.0 |
| Meningitis B M11051 Ab | 61.0 | 64.2 | 66.7 | 97.8 |
| Meningitis B M10104 Ab | 58.7 | 52.3 | 63.5 | 97.6 |
| Meningitis B M13361 Ab | 0.8 | 0.4 | 0.4 | 85.3 |
| Meningitis B M11042 Ab | 19.8 | 25.5 | 33.5 | 85.7 |
| Meningitis B M18467 Ab | 1.2 | 0.4 | 0.8 | 78.7 |
| Meningitis B M11113 Ab | 30.1 | 39.5 | 49.5 | 75.2 |
| Meningitis B M07253 Ab | 34.7 | 33.8 | 50.2 | 86.4 |
| Meningitis B M07356 Ab | 0.4 | 0 | 1.1 | 41.4 |
| Meningitis B M10710 Ab | 1.6 | 2.0 | 1.4 | 92.5 |
| Meningitis B M17147 Ab | 2.3 | 5.4 | 2.3 | 100 |
| Meningitis B M14401 Ab | 1.7 | 0.4 | 1.2 | 83.7 |
| Meningitis B M14293 Ab | 45.8 | 25.1 | 45.2 | 95.7 |
| Meningitis B M08540 Ab | 1.6 | 0.8 | 0 | 38.2 |
| Meningitis B M07960 Ab | 3.6 | 4.1 | 1.8 | 94.9 |
| Meningitis B M16135 Ab | 0 | 1.7 | 0.8 | 95.1 |
| Meningitis B M14548 Ab | 2.6 | 3.4 | 3.2 | 94.7 |
| Meningitis B M09181 Ab | 0 | 0.4 | 0.4 | 72.1 |
| Meningitis B M14224 Ab | 0.4 | 0.4 | 0 | 82.5 |
| Meningitis B M07452 Ab | 2.7 | 8.1 | 17.1 | 85.1 |
| Meningitis B M13520 Ab | 3.2 | 0.9 | 0 | 66.7 |
| Meningitis B M09385 Ab | 0.4 | 1.6 | 0 | 46.9 |
| Meningitis B M14881 Ab | 4.2 | 5.8 | 10 | 95 |
| Meningitis B M13252 Ab | 0.7 | 1.2 | 0.4 | 98 |
| Meningitis B M07818 Ab | 0.4 | 0.8 | 1.3 | 90.7 |
| Meningitis B M09914 Ab | 85.4 | 86.8 | 88.3 | 98 |
| Meningitis B M15083 Ab | 51.4 | 56.7 | 61 | 84.5 |
| Meningitis B M11290 Ab | 61.4 | 61.7 | 67.4 | 100 |
| Meningitis B M14988 Ab | 0.4 | 0 | 1.2 | 60 |
| Meningitis B M10536 Ab | 19.7 | 14.3 | 14.3 | 91.7 |
| Meningitis B M08959 Ab | 0.8 | 0.4 | 1.9 | 85.1 |
| Meningitis B M08785 Ab | 0.8 | 0.4 | 0.4 | 53.8 |
| Meningitis B M07245 Ab | 0 | 0 | 0.9 | 23.3 |
| Meningitis B M19315 Ab | 3.8 | 3.1 | 9.5 | 79.4 |
| Meningitis B M14376 Ab | 0 | 1.4 | 0 | 92.7 |
| Meningitis B M08994 Ab | 2.5 | 7.6 | 6.9 | 62.7 |
| Meningitis B M11646 Ab | 0 | 1.3 | 2 | 83.3 |
| Meningitis B M13362 Ab | 0 | 0.4 | 0.4 | 81.6 |
| Meningitis B M08080 Ab | 27.4 | 41 | 51.6 | 85.7 |
| Meningitis B M08370 Ab | 2.3 | 1.5 | 3.7 | 97.7 |
| Meningitis B M08129 Ab | 4.1 | 4.7 | 7 | 71.4 |
| Meningitis B M07111 Ab | 0.4 | 1.2 | 0.7 | 90.9 |
| Meningitis B M07537 Ab | 95.9 | 95.9 | 97.7 | 100 |
| Meningitis B M13438 Ab | 1.2 | 0.8 | 0 | 16 |
| Meningitis B M10661 Ab | 2 | 2.9 | 2.9 | 97 |
| Meningitis B M10920 Ab | 29.1 | 27.8 | 37.8 | 91.2 |
| Meningitis B M15564 Ab | 0.4 | 0.7 | 0.8 | 77.5 |
| Meningitis B M10934 Ab | 0.4 | 0.8 | 0.8 | 100 |
| Meningitis B M09400 Ab | 0.8 | 1.8 | 0.4 | 97.4 |
| Meningitis B M08781 Ab | 71.9 | 74.4 | 78.2 | 100 |
| Meningitis B M09173 Ab | 0.4 | 0.4 | 0.8 | 95.2 |
| Meningitis B M14113 Ab | 15.4 | 21.2 | 22 | 100 |
| Meningitis B M08389 Ab | 10.7 | 7 | 11.7 | 87.2 |
| Meningitis B M16822 Ab | 67.8 | 76.4 | 82.2 | 100 |
| Meningitis B M10995 Ab | 5.2 | 17.8 | 30.6 | 85.1 |
| Meningitis B M08780 Ab | 1.3 | 0.8 | 1.5 | 92.5 |
| Meningitis B M09910 Ab | 1.6 | 1.2 | 1.2 | 93 |
| Meningitis B M08320 Ab | 33.6 | 39.7 | 43.3 | 87 |
| Meningitis B M14879 Ab | 2.1 | 2.1 | 6.1 | 21.3 |
| Meningitis B M09345 Ab | 19.3 | 20.1 | 33.4 | 81.2 |
| Meningitis B M14594 Ab | 20.8 | 27.4 | 41.2 | 97.7 |
| Meningitis B M07621 Ab | 1.2 | 1.2 | 1.1 | 77.5 |
| Meningitis B M13568 Ab | 5.4 | 3.8 | 3.9 | 95 |
| Meningitis B M18017 Ab | 0.4 | 0 | 1.6 | 96.8 |
| Meningitis B M08420 Ab | 0.8 | 0.4 | 1.6 | 95 |
| Meningitis B M07959 Ab | 1.7 | 2.5 | 1.7 | 97.1 |
| Meningitis B M06970 Ab | 19.6 | 17.6 | 30.2 | 85.7 |
| Meningitis B M10491 Ab | 5.4 | 8.4 | 17 | 82.1 |
| Meningitis B M13569 Ab | 0.9 | 2.9 | 1.2 | 96.8 |
| Meningitis B M10182 Ab | 0.4 | 0 | 0 | 0 |
| Meningitis B M13547 Ab | 2.4 | 7 | 4.7 | 47.7 |
| Meningitis B M15276 Ab | 0.4 | 0 | 1.5 | 87.8 |
The effectiveness of the 2 dose (0,2-M) schedule of rMenB+OMV NZ vaccine when compared to 1 month after the MenACWY vaccination (Day 31), against a panel of N. meningitidis serogroup B strains is measured in terms of percentage of samples without bactericidal activity using enc-hSBA, which provides a qualitative assessment (yes/no) of the presence of sufficient bactericidal antibodies in human sera to kill a meningococcal strain at a specific dilution of 1:4.
| Percentage of blood samples | MenB_0_2_6 Group | ACWY Group |
|---|---|---|
| Meningitis B M10713 Ab | 1.9 | 15.6 |
| Meningitis B M08641 Ab | 11.2 | 96.6 |
| Meningitis B M12898 Ab | 12.4 | 69 |
| Meningitis B M09150 Ab | 9.3 | 68.6 |
| Meningitis B M09401 Ab | 47 | 98 |
| Meningitis B M07463 Ab | 2.6 | 49 |
| Meningitis B M10496 Ab | 50.5 | 100 |
| Meningitis B M14530 Ab | 3.9 | 100 |
| Meningitis B M15668 Ab | 0.4 | 87.8 |
| Meningitis B M14028 Ab | 5.4 | 100 |
| Meningitis B M09909 Ab | 82 | 100 |
| Meningitis B M14385 Ab | 0 | 16.3 |
| Meningitis B M07992 Ab | 0 | 0 |
| Meningitis B M09155 Ab | 2.5 | 97.8 |
| Meningitis B M13085 Ab | 21 | 66.4 |
| Meningitis B M18303 Ab | 9.1 | 100 |
| Meningitis B M18711 Ab | 7.7 | 75.8 |
| Meningitis B M15009 Ab | 22.2 | 86.5 |
| Meningitis B M07773 Ab | 1.1 | 74.3 |
| Meningitis B M09662 Ab | 58.1 | 95.8 |
| Meningitis B M18483 Ab | 4.3 | 77.3 |
| Meningitis B M11906 Ab | 38.8 | 85.3 |
| Meningitis B M14987 Ab | 10.7 | 62.3 |
| Meningitis B M12014 Ab | 0.7 | 63.2 |
| Meningitis B M18200 Ab | 12.1 | 34.4 |
| Meningitis B M08912 Ab | 0 | 0 |
| Meningitis B M16748 Ab | 0 | 0 |
| Meningitis B M08152 Ab | 35.6 | 67.2 |
| Meningitis B M09973 Ab | 1.5 | 83.3 |
| Meningitis B M15352 Ab | 11.9 | 97 |
| Meningitis B M15165 Ab | 0.8 | 92.9 |
| Meningitis B M08127 Ab | 0.4 | 84.3 |
| Meningitis B M18347 Ab | 60.5 | 80.4 |
| Meningitis B M12500 Ab | 3.4 | 95.3 |
| Meningitis B M07499 Ab | 81.1 | 100 |
| Meningitis B M09960 Ab | 4.4 | 3 |
| Meningitis B M18045 Ab | 0 | 92.7 |
| Meningitis B M10548 Ab | 11.9 | 74.1 |
| Meningitis B M09354 Ab | 0.4 | 80 |
| Meningitis B M11051 Ab | 68.9 | 97.8 |
| Meningitis B M10104 Ab | 61.8 | 97.6 |
| Meningitis B M13361 Ab | 0.4 | 85.3 |
| Meningitis B M11042 Ab | 30.1 | 84.2 |
| Meningitis B M18467 Ab | 0.4 | 78.7 |
| Meningitis B M11113 Ab | 43.1 | 75.6 |
| Meningitis B M07253 Ab | 43.3 | 85.3 |
| Meningitis B M07356 Ab | 0 | 41.4 |
| Meningitis B M10710 Ab | 2.2 | 92.5 |
| Meningitis B M17147 Ab | 5.1 | 100 |
| Meningitis B M14401 Ab | 0.8 | 83.7 |
| Meningitis B M14293 Ab | 36.4 | 95.7 |
| Meningitis B M08540 Ab | 0.4 | 38.2 |
| Meningitis B M07960 Ab | 4.1 | 94.9 |
| Meningitis B M16135 Ab | 0.8 | 95.1 |
| Meningitis B M14548 Ab | 2.8 | 94.7 |
| Meningitis B M09181 Ab | 0 | 72.1 |
| Meningitis B M14224 Ab | 0.7 | 82.5 |
| Meningitis B M07452 Ab | 13.5 | 85.1 |
| Meningitis B M13520 Ab | 0.9 | 66.7 |
| Meningitis B M09385 Ab | 2.2 | 46.9 |
| Meningitis B M14881 Ab | 14.7 | 95 |
| Meningitis B M13252 Ab | 3.1 | 98 |
| Meningitis B M07818 Ab | 0.4 | 90.7 |
| Meningitis B M09914 Ab | 87.7 | 98 |
| Meningitis B M15083 Ab | 63.7 | 78 |
| Meningitis B M11290 Ab | 70.5 | 100 |
| Meningitis B M14988 Ab | 0.4 | 60 |
| Meningitis B M10536 Ab | 23.2 | 91.7 |
| Meningitis B M08959 Ab | 0.4 | 85.1 |
| Meningitis B M08785 Ab | 0.4 | 53.8 |
| Meningitis B M07245 Ab | 0 | 23.3 |
| Meningitis B M19315 Ab | 6.3 | 79.4 |
| Meningitis B M14376 Ab | 0 | 92.7 |
| Meningitis B M08994 Ab | 8.9 | 55.7 |
| Meningitis B M11646 Ab | 1.6 | 83.3 |
| Meningitis B M13362 Ab | 1.5 | 81.6 |
| Meningitis B M08080 Ab | 46.8 | 87.1 |
| Meningitis B M08370 Ab | 3.9 | 97.7 |
| Meningitis B M08129 Ab | 7.4 | 71.4 |
| Meningitis B M07111 Ab | 0.4 | 90.9 |
| Meningitis B M07537 Ab | 96.4 | 100 |
| Meningitis B M13438 Ab | 0.4 | 16 |
| Meningitis B M10661 Ab | 2.7 | 97 |
| Meningitis B M10920 Ab | 50.2 | 91.2 |
| Meningitis B M15564 Ab | 0.8 | 77.5 |
| Meningitis B M10934 Ab | 0 | 100 |
| Meningitis B M09400 Ab | 1.1 | 97.4 |
| Meningitis B M08781 Ab | 75.8 | 100 |
| Meningitis B M09173 Ab | 0 | 95.2 |
| Meningitis B M14113 Ab | 28.3 | 100 |
| Meningitis B M08389 Ab | 1.9 | 86.7 |
| Meningitis B M16822 Ab | 85 | 100 |
| Meningitis B M10995 Ab | 16.3 | 85.1 |
| Meningitis B M08780 Ab | 0.8 | 92.5 |
| Meningitis B M09910 Ab | 1.2 | 93 |
| Meningitis B M08320 Ab | 45.1 | 86.8 |
| Meningitis B M14879 Ab | 3.3 | 23.2 |
| Meningitis B M09345 Ab | 32.3 | 74.9 |
| Meningitis B M14594 Ab | 35.8 | 97.7 |
| Meningitis B M07621 Ab | 0.4 | 77.5 |
| Meningitis B M13568 Ab | 9.7 | 95 |
| Meningitis B M18017 Ab | 0 | 96.8 |
| Meningitis B M08420 Ab | 0.8 | 95 |
| Meningitis B M07959 Ab | 1.2 | 97.1 |
| Meningitis B M06970 Ab | 28.8 | 90.6 |
| Meningitis B M10491 Ab | 16.1 | 82.1 |
| Meningitis B M13569 Ab | 0.4 | 96.8 |
| Meningitis B M10182 Ab | 0 | 0 |
| Meningitis B M13547 Ab | 5 | 47.7 |
| Meningitis B M15276 Ab | 0.4 | 87.8 |
The percentage of participants classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Percentage of participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled |
|---|---|---|---|
| >=50% killed strains | 98.7 ± 97.7 | 98.5 ± 97.4 | 98 ± 96.8 |
| >=55% killed strains | 98.4 ± 97.2 | 97.4 ± 96.1 | 96.8 ± 95.4 |
| >=60% killed strains | 97.8 ± 96.6 | 96.8 ± 95.3 | 95.2 ± 93.5 |
| >=65% killed strains | 96.5 ± 94.9 | 93.6 ± 91.7 | 90.1 ± 87.8 |
| >=70% killed strains | 93.4 ± 91.5 | 89.8 ± 87.5 | 84.1 ± 81.4 |
| >=75% killed strains | 86.8 ± 84.3 | 82.2 ± 79.4 | 74.7 ± 71.5 |
| >=80% killed strains | 79.2 ± 76.2 | 75.5 ± 72.4 | 66 ± 62.6 |
| >=85% killed strains | 62.8 ± 59.3 | 60.4 ± 56.9 | 50.1 ± 46.6 |
| >=90% killed strains | 43.7 ± 40.2 | 41.3 ± 37.9 | 32.1 ± 28.9 |
| >=95% killed strains | 22.5 ± 19.7 | 21 ± 18.3 | 13.7 ± 11.4 |
| 100% killed strains | 10 ± 8 | 8.4 ± 6.6 | 6.1 ± 4.6 |
The percentage of participants classified by percentage of N.meningitidis serogroup B invasive strains killed using enc-hSBA and the corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group.
| Percentage of participants | MenB_0_2_6 Group |
|---|---|
| >=50% killed strains | 98.6 ± 97.5 |
| >=55% killed strains | 97.7 ± 96.5 |
| >=60% killed strains | 96.5 ± 95 |
| >=65% killed strains | 92.2 ± 90.1 |
| >=70% killed strains | 84.8 ± 82.2 |
| >=75% killed strains | 75.7 ± 72.6 |
| >=80% killed strains | 66.7 ± 63.3 |
| >=85% killed strains | 49.7 ± 46.2 |
| >=90% killed strains | 33.8 ± 30.6 |
| >=95% killed strains | 16.2 ± 13.8 |
| 100% killed strains | 7.7 ± 6 |
The immune response to rMenB+OMV NZ and MenABCWY vaccine is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains(M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively). As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Percentage of participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled |
|---|---|---|---|
| fHbp (M14459) Ab, Day 1 | 4.9 (3.5 to 6.7) | 3.4 (2.2 to 5) | 5.4 (3.9 to 7.2) |
| fHbp (M14459) Ab, Day 211 | 97.4 (95.9 to 98.4) | 94.6 (92.7 to 96.2) | 95.9 (94.2 to 97.2) |
| NadA (96217) Ab, Day 1 | 6.2 (4.6 to 8.2) | 4.4 (3.0 to 6.1) | 6.2 (4.6 to 8.1) |
| NadA (96217) Ab, Day 211 | 100 (99.5 to 100) | 98 (96.7 to 98.9) | 96.2 (94.5 to 97.5) |
| NHBA (M13520) Ab, Day 1 | 23.2 (20.3 to 26.4) | 20.9 (18 to 24.1) | 18.5 (15.8 to 21.4) |
| NHBA (M13520) Ab, Day 211 | 97.0 (95.4 to 98.1) | 97.5 (96.0 to 98.5) | 95.3 (93.5 to 96.7) |
| PorA (NZ98/254) Ab, Day 1 | 2.3 (1.3 to 3.7) | 1.4 (0.7 to 2.6) | 2.1 (1.2 to 3.4) |
| PorA (NZ98/254) Ab, Day 211 | 85.8 (82.9 to 88.4) | 82.6 (79.5 to 85.4) | 75.3 (72.0 to 78.5) |
| Composite Response, Day=1 | 1.1 (0.5 to 2.2) | 0.6 (0.2 to 1.4) | 1.1 (0.5 to 2.1) |
| Composite Response, Day=211 | 83.3 (80.3 to 86.1) | 80.7 (77.5 to 83.6) | 71.4 (67.9 to 74.7) |
The immune response to rMenB+OMV NZ is evaluated by measuring bactericidal activity against each (individual response) and all (composite response) N. meningitidis serogroup B indicator strains (M14459, 96217, M13520 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively).
| Percentage of participants | MenB_0_2_6 Group |
|---|---|
| fHbp (M14459) Ab, Day 1 | 4.9 (3.5 to 6.7) |
| fHbp (M14459) Ab, Day 91 | 92.9 (90.9 to 94.7) |
| NadA (96217) Ab, Day 1 | 6.2 (4.6 to 8.2) |
| NadA (96217) Ab, Day 91 | 99.5 (98.6 to 99.9) |
| NHBA, Day 1 | 23.2 (20.3 to 26.4) |
| NHBA (M13520) Ab, Day 91 | 96.1 (94.5 to 97.4) |
| PorA N (NZ98/254) Ab, Day 1 | 2.3 (1.3 to 3.7) |
| PorA N (NZ98/254) Ab, Day 91 | 80 (76.9 to 82.8) |
| Composite Response, Day=1 | 1.1 (0.5 to 2.2) |
| Composite Response, Day=91 | 75.5 (72.3 to 78.6) |
The immune response to 3 dose (0,2,6-M), 2 dose (0,6-M) schedule of rMenB+OMV NZ and 2 doses of MenABCWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for subjects with a pre-vaccination hSBA titre \<4 a post-vaccination hSBA titer ≥4 times the LLOQ for subjects with a pre-vaccination hSBA titre ≥LOD and \<LLOQ a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for participants with a pre-vaccination hSBA titre ≥ LLOQ. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Percentage of participants | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled |
|---|---|---|---|
| fHbp (M14459) Ab | 86.7 (84.0 to 89.2) | 82.4 (79.4 to 85.2) | 78.9 (75.7 to 81.8) |
| NadA (96217) Ab | 98.7 (97.5 to 99.4) | 95.3 (93.4 to 96.7) | 92.3 (90.1 to 94.1) |
| NHBA (M13520) Ab | 66.9 (63.2 to 70.4) | 69.5 (65.9 to 72.8) | 61.1 (57.5 to 64.7) |
| PorA (NZ98/254) Ab | 56.5 (52.6 to 60.4) | 57.2 (53.4 to 61.0) | 42.4 (38.7 to 46.2) |
The immune response to 2 dose (0,2-M) is evaluated by measuring bactericidal activity against each of the N. meningitidis serogroup B test strains- M14459, 96217, NZ98/254 and M13520 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively compared to baseline. Four-fold rise per each indicator strain was defined as a post-vaccination hSBA titre ≥16 for participants with a pre-vaccination hSBA titre \<4 a post-vaccination hSBA titre ≥4 times the LLOQ for subjects with a pre-vaccination hSBA titre ≥LOD and \<LLOQ a post-vaccination hSBA titre ≥4 times the pre-vaccination hSBA titre for subjects with a pre-vaccination hSBA titre ≥ LLOQ.
| Percentage of participants | MenB_0_2_6 Group |
|---|---|
| fHbp (M14459) Ab | 74.6 (71.3 to 77.7) |
| NadA (96217) Ab | 96.3 (94.7 to 97.6) |
| NHBA (M13520) Ab | 58.5 (54.8 to 62.0) |
| PorA (NZ98/254) Ab | 53.5 (49.7 to 57.1) |
The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Titers | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled |
|---|---|---|---|
| fHbp (M14459) Ab, Day 1 | 2.8 (2.7 to 2.8) | 2.7 (2.6 to 2.8) | 2.8 (2.7 to 2.9) |
| fHbp (M14459) Ab, Day 211 | 30.8 (28.3 to 33.5) | 28.1 (25.9 to 30.6) | 25 (23 to 27.1) |
| NadA (96217) Ab, Day 1 | 8.4 (8.1 to 8.6) | 8.3 (8 to 8.6) | 8.5 (8.2 to 8.8) |
| NadA (96217) Ab, Day 211 | 267.2 (243.7 to 293) | 215.1 (196.2 to 235.9) | 150.6 (137.3 to 165.2) |
| NHBA (M13520) Ab, Day 1 | 3.4 (3.1 to 3.7) | 3.2 (3 to 3.5) | 3.1 (2.8 to 3.4) |
| NHBA (M13520) Ab, Day 211 | 30.6 (27.7 to 33.7) | 33.2 (30.2 to 36.6) | 25.2 (22.9 to 27.8) |
| PorA (NZ98/254) Ab, Day 1 | 3.2 (3.1 to 3.2) | 3.1 (3 to 3.2) | 3.1 (3.1 to 3.2) |
| PorA (NZ98/254) Ab, Day 211 | 18.1 (16.3 to 20.1) | 17.7 (15.9 to 19.6) | 12.9 (11.6 to 14.4) |
The immune response to rMenB+OMV NZ and MenABCWY vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), The GMTs (After vaccination/baseline) were calculated, with their associated 2-sided 95% CIs.
| Titers | MenB_0_2_6 Group |
|---|---|
| fHbp (M14459) Ab, Day 1 | 2.8 (2.7 to 2.8) |
| fHbp (M14459) Ab, Day 91 | 20.9 (18.9 to 23.1) |
| NadA (96217) Ab, Day 1 | 8.4 (8.1 to 8.6) |
| NadA (96217) Ab, Day 91 | 178.5 (161.7 to 197.2) |
| NHBA (M13520) Ab, Day 1 | 3.4 (3.1 to 3.7) |
| NHBA (M13520) Ab, Day 91 | 27.2 (24.1 to 30.6) |
| PorA (NZ98/254) Ab, Day 1 | 3.2 (3.1 to 3.2) |
| PorA (NZ98/254) Ab, Day 91 | 17.1 (15.2 to 19.3) |
The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the MenB_0_2_6 group, MenB_0_6 group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Ratio | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled |
|---|---|---|---|
| fHbp (M14459) Ab | 11.2 (10.3 to 12.2) | 10.5 (9.6 to 11.4) | 9 (8.2 to 9.8) |
| NadA (96217) Ab | 32.1 (29.1 to 35.3) | 25.8 (23.5 to 28.4) | 17.7 (16 to 19.4) |
| NHBA (M13520) Ab | 9.1 (8.2 to 10.1) | 10.6 (9.5 to 11.7) | 8.2 (7.4 to 9.1) |
| PorA (NZ98/254) Ab | 5.8 (5.2 to 6.5) | 5.8 (5.2 to 6.4) | 4.1 (3.7 to 4.6) |
The immune response to rMenB+OMV NZ vaccine was evaluated by measuring bactericidal activity against N. meningitidis serogroup B test strains after vaccination compared to baseline (Day 1). For each N. meningitidis serogroup B test strain (M14459, M13520, 96217 and NZ98/254 for fHbp, NadA, NHBA and PorA P1.4 antigens, respectively), the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs.
| Ratio | MenB_0_2_6 Group |
|---|---|
| fHbp (M14459) Ab | 7.7 (6.9 to 8.5) |
| NadA (96217) Ab | 21.7 (19.5 to 24) |
| NHBA (M13520) Ab | 8 (7.1 to 9) |
| PorA (NZ98/254) Ab | 5.5 (4.9 to 6.2) |
The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y after vaccination compared to baseline (Day 1) and expressed as the percentage of participants with hSBA titers \>= LLOQ for serogroups A, C, W and Y at baseline and 1 month after vaccination schedule of MenABCWY and MenACWY vaccines. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Percentage of participants | ABCWY_Pooled | ACWY Group |
|---|---|---|
| Men A, Day 1 | 9.2 (7.7 to 10.8) | 11.7 (6.8 to 18.3) |
| Men A, Day 31 | 79.5 (71.7 to 86.1) | 90.2 (83.9 to 94.7) |
| Men A, Day 211 | 98.6 (97.9 to 99.2) | — |
| Men C, Day 1 | 29.8 (27.5 to 32.2) | 28.8 (21.4 to 37.1) |
| Men C, Day 31 | 74.8 (66.8 to 81.8) | 64.0 (55.3 to 72.0) |
| Men C, Day 211 | 99.6 (99.1 to 99.8) | — |
| Men W, Day 1 | 12.6 (10.9 to 14.4) | 12.9 (7.8 to 19.6) |
| Men W, Day 31 | 80.3 (72.8 to 86.5) | 69.3 (60.9 to 76.9) |
| Men W, Day 211 | 99.2 (98.7 to 99.6) | — |
| Men Y, Day 1 | 12.2 (10.6 to 14.0) | 13.5 (8.3 to 20.2) |
| Men Y, Day 31 | 82.2 (75.0 to 88.0) | 80.0 (72.4 to 86.3) |
| Men Y, Day 211 | 99.2 (98.7 to 99.6) | — |
The immune response to MenABCWY vaccine compared to MenACWY vaccine was evaluated by measuring bactericidal activity against each of the N. meningitidis serogroups A, C, W and Y at Day 31 compared to baseline (Day 1). Four-fold rise is defined as: - If the pre-vaccination hSBA titer is \< 4, then post-vaccination hSBA titer should be ≥ 16. - If the pre-vaccination hSBA titer is ≥ LOD but \< LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the LLOQ. - If the pre-vaccination hSBA titer is ≥ LLOQ, then post-vaccination hSBA titer should be ≥ 4 times the pre-vaccination hSBA titer. The corresponding 2- sided 95% CI based on Clopper-Pearson method is calculated for each vaccine group. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Percentage of participants | ABCWY_Pooled | ACWY Group |
|---|---|---|
| Men A | 74.0 (65.5 to 81.4) | 86.0 (78.8 to 91.5) |
| Men C | 66.9 (58.4 to 74.6) | 56.7 (47.9 to 65.2) |
| Men W | 74.1 (66.0 to 81.2) | 66.2 (57.6 to 74.1) |
| Men Y | 76.0 (68.3 to 82.7) | 72.1 (63.9 to 79.4) |
The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y in terms of GMTs after vaccination compared to baseline (Day 1). For each N. meningitidis serogroups A, C, W and Y, the GMTs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Titers | ABCWY_Pooled | ACWY Group |
|---|---|---|
| Men A, Day 1 | 11.1 (10.3 to 11.9) | 12.7 (10.9 to 14.8) |
| Men A, Day 31 | 175.3 (121.2 to 253.3) | 474.8 (331.3 to 680.3) |
| Men A, Day 211 | 352.0 (322.0 to 384.7) | — |
| Men C, Day 1 | 12.0 (10.9 to 13.3) | 11.4 (9.1 to 14.3) |
| Men C, Day 31 | 674.8 (355.9 to 1279.4) | 379.0 (204.4 to 703.0) |
| Men C, Day 211 | 1162.5 (1015.7 to 1330.5) | — |
| Men W, Day 1 | 8.0 (7.4 to 8.7) | 7.4 (6.2 to 8.9) |
| Men W, Day 31 | 374.0 (243.4 to 574.8) | 194.3 (128.3 to 294.2) |
| Men W, Day 211 | 666.5 (603.2 to 736.3) | — |
| Men Y, Day 1 | 9.3 (8.7 to 10.0) | 9.9 (8.6 to 11.5) |
| Men Y, Day 31 | 375.4 (246.9 to 570.7) | 320.9 (213.8 to 481.7) |
| Men Y, Day 211 | 655.9 (587.0 to 733.0) | — |
The immune responses to MenABCWY and MenACWY vaccines are evaluated by measuring bactericidal activity against N. meningitidis serogroups A, C, W and Y. For each N. meningitidis serogroups A, C, W and Y, the GMRs (after vaccination/baseline) are calculated, with their associated 2-sided 95% CIs. As pre-specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| Ratio | ABCWY_Pooled | ACWY Group |
|---|---|---|
| Men A, Day 31 | 11.8 (7.9 to 17.7) | 31.8 (21.4 to 47.1) |
| Men A, Day 211 | 31.2 (28.3 to 34.5) | — |
| Men C, Day 31 | 30.9 (16.9 to 56.2) | 22.9 (12.8 to 41.1) |
| Men C, Day 211 | 96.9 (84.5 to 111.1) | — |
| Men W, Day 31 | 32.9 (21.7 to 50.0) | 23.2 (15.5 to 34.7) |
| Men W, Day 211 | 83.8 (74.9 to 93.8) | — |
| Men Y, Day 31 | 28.1 (18.3 to 43.2) | 25.6 (16.9 to 38.8) |
| Men Y, Day 211 | 70.2 (62.3 to 79.1) | — |
The immune responses to MenABCWY and MenACWY vaccines were evaluated by measuring the total IgG in terms of electrochemiluminescence-based multiplex (ECL) geometric mean concentrations (GMCs) which was an alternative assay to Enzyme-Linked Immunosorbent Assay (ELISA). ECL (validated assay) was used because ELISA is not validated. As pre- specified in the protocol, data reported in this outcome measure were presented for the ACWY group and ABCWY pooled group, participants from the ABCWY-1, ABCWY-2, and ABCWY-3 groups were pooled into a single group.
| microgram per milliliter(µg/mL) | ACWY Group | ABCWY_Pooled |
|---|---|---|
| Men A, Day 1 | 2.3 (2.0 to 2.7) | 1.9 (1.6 to 2.2) |
| Men A, Day 31 | 53.7 (40.8 to 70.7) | 18.1 (13.8 to 23.8) |
| Men A, Day 211 | — | 30.2 (23.3 to 39.2) |
| Men C, Day 1 | 0.8 (0.7 to 1.0) | 0.7 (0.6 to 0.8) |
| Men C, Day 31 | 13.8 (10.4 to 18.4) | 15.5 (11.6 to 20.7) |
| Men C, Day 211 | — | 17.0 (13.1 to 22.0) |
| Men W, Day 1 | 0.6 (0.5 to 0.7) | 0.5 (0.4 to 0.6) |
| Men W, Day 31 | 8.4 (6.0 to 11.6) | 9.1 (6.5 to 12.8) |
| Men W, Day 211 | — | 21.7 (16.0 to 29.5) |
| Men Y, Day 1 | 0.9 (0.8 to 1.0) | 0.9 (0.7 to 1.0) |
| Men Y, Day 31 | 14.3 (10.2 to 19.8) | 12.9 (9.2 to 18.0) |
| Men Y, Day 211 | — | 26.3 (19.6 to 35.4) |
Collected over SAEs and Non-serious AEs (Other AEs) were collected through the entire period of the study (from Day 1 up to study end [Day 361]). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MenB_0_2_6 Group | 1/897 (0.1%) | 20/897 (2.2%) | 876/897 (97.7%) |
| MenB_0_6 Group | 1/906 (0.1%) | 22/906 (2.4%) | 872/906 (96.2%) |
| ACWY Group | 0/178 (0%) | 5/178 (2.8%) | 173/178 (97.2%) |
| ABCWY-1 Group | 0/549 (0%) | 8/549 (1.5%) | 529/549 (96.4%) |
| ABCWY-2 Group | 0/554 (0%) | 9/554 (1.6%) | 537/554 (96.9%) |
| ABCWY-3 Group | 0/554 (0%) | 8/554 (1.4%) | 544/554 (98.2%) |
| Event | MenB_0_2_6 Group | MenB_0_6 Group | ACWY Group | ABCWY-1 Group | ABCWY-2 Group | ABCWY-3 Group |
|---|---|---|---|---|---|---|
| Mental disorderPsychiatric disorders | 0/897 | 0/906 | 0/178 | — | 1/1 | — |
| Chest painGeneral disorders | 0/897 | 0/906 | 1/178 | 0/549 | 0/554 | 0/554 |
| ConcussionInjury, poisoning and procedural complications | 3/897 | 0/906 | 1/178 | 0/549 | 1/554 | 0/554 |
| Troponin T increasedInvestigations | 0/897 | 0/906 | 1/178 | 0/549 | 0/554 | 0/554 |
| Testis cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/897 | 0/906 | 1/178 | — | — | — |
| AphasiaNervous system disorders | 0/897 | 0/906 | 1/178 | 0/549 | 0/554 | 0/554 |
| DizzinessNervous system disorders | 0/897 | 0/906 | 1/178 | 0/549 | 0/554 | 0/554 |
| DysarthriaNervous system disorders | 0/897 | 0/906 | 1/178 | 0/549 | 0/554 | 0/554 |
| Speech disorderNervous system disorders | 0/897 | 0/906 | 1/178 | 0/549 | 0/554 | 0/554 |
| DepressionPsychiatric disorders | 0/897 | 2/906 | 1/178 | 0/549 | 0/554 | 0/554 |
| Event | MenB_0_2_6 Group | MenB_0_6 Group | ACWY Group | ABCWY-1 Group | ABCWY-2 Group | ABCWY-3 Group |
|---|---|---|---|---|---|---|
| Lower limb fractureInjury, poisoning and procedural complications | 1/897 | 0/906 | 0/178 | — | 1/1 | — |
| Administration site painGeneral disorders | 851/897 | 853/906 | 149/178 | 515/549 | 522/554 | 524/554 |
| FatigueGeneral disorders | 604/897 | 579/906 | 105/178 | 352/549 | 356/554 | 358/554 |
| HeadacheNervous system disorders | 578/897 | 525/906 | 97/178 | 300/549 | 309/554 | 320/554 |
| NauseaGastrointestinal disorders | 245/897 | 204/906 | 45/178 | 121/549 | 138/554 | 139/554 |
| MyalgiaMusculoskeletal and connective tissue disorders | 240/897 | 209/906 | 30/178 | 122/549 | 132/554 | 130/554 |
| Administration site erythemaGeneral disorders | 209/897 | 157/906 | 21/178 | 112/549 | 115/554 | 94/554 |
| Administration site swellingGeneral disorders | 202/897 | 158/906 | 22/178 | 101/549 | 109/554 | 95/554 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 154/897 | 127/906 | 25/178 | 84/549 | 76/554 | 76/554 |
| Administration site indurationGeneral disorders | 138/897 | 113/906 | 17/178 | 73/549 | 78/554 | 72/554 |
As pre-specified in the protocol, data reported in the Baseline characteristics are presented for MenB_0_2_6 group, MenB_0_6 group, ACWY group, ABCWY pooled group.
| Age, Continuous(years) | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group | Total |
|---|---|---|---|---|---|
| Mean | 16.5 ± 4.7 | 16.5 ± 4.7 | 16.5 ± 4.7 | 16.9 ± 4.6 | 16.5 ± 4.7 |
| Sex: Female, Male(Participants) | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group | Total |
|---|---|---|---|---|---|
| Female | 464 | 446 | 933 | 100 | 1943 |
| Male | 433 | 460 | 724 | 78 | 1695 |
| Race/Ethnicity, Customized(Participants) | MenB_0_2_6 Group | MenB_0_6 Group | ABCWY_Pooled | ACWY Group | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 5 | 5 | 3 | 0 | 13 |
| Asian | 43 | 60 | 71 | 9 | 183 |
| Black or African American | 33 | 29 | 59 | 6 | 127 |
| Native Hawaiian or Other Pacific Islander | 3 | 1 | 3 | 0 | 7 |
| White | 796 | 791 | 1492 | 162 | 3241 |
| Other, Unspecified | 17 | 20 | 29 | 1 | 67 |
Showing the first 100 of 112 sites across 7 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Ran from Aug 2020 to primary completion in Sep 2022, 24 months.
Results were first posted in Mar 2024, 1 year 5 months after primary completion. A results delay was requested in Sep 2023.
Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 24 months is above that.
Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: 4CMenB vaccine · MenACWY